BR9911294A - Composição para o tratamento de imuno deficiências e métodos para sua preparação e uso - Google Patents

Composição para o tratamento de imuno deficiências e métodos para sua preparação e uso

Info

Publication number
BR9911294A
BR9911294A BR9911294-9A BR9911294A BR9911294A BR 9911294 A BR9911294 A BR 9911294A BR 9911294 A BR9911294 A BR 9911294A BR 9911294 A BR9911294 A BR 9911294A
Authority
BR
Brazil
Prior art keywords
immune deficiencies
preparation
treatment
composition
methods
Prior art date
Application number
BR9911294-9A
Other languages
English (en)
Other versions
BR9911294B1 (pt
Inventor
Oleg Strelchenok
Original Assignee
Ardenia Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardenia Investments Ltd filed Critical Ardenia Investments Ltd
Publication of BR9911294A publication Critical patent/BR9911294A/pt
Publication of BR9911294B1 publication Critical patent/BR9911294B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSIçãO PARA O TRATAMENTO DE IMUNO DEFICIêNCIAS E MéTODOS PARA SUA PREPARAçãO E USO". Um complexo de alfa-fetoproteína (AFP) e N-araquidonoil aminoetil fosfato (N-AAP) mostra possuir significantes propriedades imunoestimuladoras e pode, consequentemente, ser usado como um agente terapêutico em várias indicações, tais como imuno deficiências, e em particular imuno deficiências relacionadas à terapia de câncer.
BRPI9911294-9A 1998-06-17 1999-06-17 complexo reversìvel de equilìbrio, preparação liofilizada, solução injetável e composição farmacêutica. BR9911294B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9802162-9 1998-06-17
SE9802162A SE9802162D0 (sv) 1998-06-17 1998-06-17 Immunostimulating composition
PCT/EP1999/004201 WO1999065936A2 (en) 1998-06-17 1999-06-17 Composition for the treatement of immune deficiencies and methods for its preparation and use

Publications (2)

Publication Number Publication Date
BR9911294A true BR9911294A (pt) 2002-01-02
BR9911294B1 BR9911294B1 (pt) 2012-01-10

Family

ID=20411743

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9911294-9A BR9911294B1 (pt) 1998-06-17 1999-06-17 complexo reversìvel de equilìbrio, preparação liofilizada, solução injetável e composição farmacêutica.

Country Status (11)

Country Link
US (1) US6599507B2 (pt)
EP (1) EP1085909B1 (pt)
JP (1) JP4392991B2 (pt)
AT (1) ATE314094T1 (pt)
AU (1) AU748838B2 (pt)
BR (1) BR9911294B1 (pt)
CA (1) CA2335079C (pt)
DE (1) DE69929189T2 (pt)
HK (1) HK1035866A1 (pt)
SE (1) SE9802162D0 (pt)
WO (1) WO1999065936A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802162D0 (sv) 1998-06-17 1998-06-17 Nomet Management Services Bv Immunostimulating composition
SE9900941D0 (sv) * 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
DE69909137T2 (de) * 1999-03-16 2004-05-19 Ardenia Investments Ltd. Polyungesättigte Fettsäurederivate und deren Verwendung in der Krebsbehandlung
ES2272490T3 (es) * 2000-07-12 2007-05-01 Ardenia Investments Ltd. Nuevos compuestos citotoxicos y su uso.
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096863A (en) * 1996-08-23 2000-08-01 Regents Of The University Of Minnesota Self-assembling amphiphiles for construction of peptide secondary structures
SE9802162D0 (sv) 1998-06-17 1998-06-17 Nomet Management Services Bv Immunostimulating composition

Also Published As

Publication number Publication date
DE69929189D1 (de) 2006-02-02
US6599507B2 (en) 2003-07-29
WO1999065936A2 (en) 1999-12-23
AU748838B2 (en) 2002-06-13
JP2004500315A (ja) 2004-01-08
BR9911294B1 (pt) 2012-01-10
CA2335079A1 (en) 1999-12-23
HK1035866A1 (en) 2001-12-14
JP4392991B2 (ja) 2010-01-06
ATE314094T1 (de) 2006-01-15
EP1085909B1 (en) 2005-12-28
CA2335079C (en) 2008-01-08
SE9802162D0 (sv) 1998-06-17
WO1999065936A3 (en) 2000-02-10
US20010034324A1 (en) 2001-10-25
DE69929189T2 (de) 2006-08-31
EP1085909A2 (en) 2001-03-28
AU4773499A (en) 2000-01-05

Similar Documents

Publication Publication Date Title
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
BR0206985A (pt) Anticorpos modificados e métodos de uso
BR0015194A (pt) Uso de um inibidor de egfr-tirosina-quinase, e, métodos para redução da transformação de células epiteliais e para causar reversão substancial de tecido epitelial
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
IT1238231B (it) Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
MY138883A (en) Use of asiatic acid for treatment of cencer
ATE215540T1 (de) Benzofuran-carboxamide und -sulfonamide
ES2009140A6 (es) Un metodo de produccion de anticuerpos monoclonales humanos de proteccion cruzada y de composiciones que los contienen.
ES2107511T3 (es) Procedimiento para la preparacion de un concentrado de factor xi de la coagulacion sanguinea con alta actividad especifica, apropiado para su uso terapeutico.
HK1048308A1 (en) Novel compounds.
BR9911294A (pt) Composição para o tratamento de imuno deficiências e métodos para sua preparação e uso
FI904025A0 (fi) Halogenalkylfenylalkoholer.
BG101126A (en) The use of muramylpeptide compounds
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
BR9908443A (pt) Linhagens de células de medula espinhal humana e métodos para uso das mesmas
GR3018632T3 (en) Beta-alethine use in cell culture and therapy.
IT8920357A0 (it) Nuovi derivati della serina, loro processo di preparazione e impiego in terapia umana.
PT98764A (pt) Processo para a preparacao de composicoes contendo factor de desenvolvimento de insulina 1 completo para o tratamento terapeutico ou profilactico de estado catabolicos
DE60037402D1 (de) Behandlung von autoimmunkrankheiten mit einem extrakt von amerikanischem ginseng
RU94024337A (ru) Антиметастатическое средство
IT8619457A1 (it) Derivati insaturi cicloalifatici, loro procedimenti di preparazione e loro impiego in terapia e in cosmetica
Fueki The Structure to realize the Right of Public Assistance and the Solidarity

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/01/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2518 DE 09-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.